ArticleLeukemia2017

A TLR7 agonist enhances the antitumor efficacy of obinutuzumab in murine lymphoma models via NK cells and CD4 T cells.

E J Cheadle et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.